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A B S T R A C T   
The aim of this study is to analyze the concentrations of cytokines in tear of hospitalized COVID-19 patients 
compared to healthy controls. Tear samples were obtained from 41 healthy controls and 62 COVID-19 patients. 
Twenty-seven cytokines were assessed: interleukin (IL)-1b, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL9, IL-10, IL- 
12, IL-13, IL-15, IL-17, eotaxin, fibroblast growth factor basic, granulocyte colony-stimulating factor (G-CSF), 
granulocyte-monocyte colony-stimulating factor (GM-CSF), interferon (IFN)-γ, interferon gamma-induced pro-
tein, monocyte chemo-attractant protein-1, macrophage inflammatory protein (MIP)-1a, MIP-1b, platelet- 
derived growth factor (PDGF), regulated on activation normal T cell expressed and secreted, tumor necrosis 
factor-α and vascular endothelial growth factor (VEGF). 
In tear samples of COVID-19 patients, an increase in IL-9, IL-15, G-CSF, GM-CSF, IFN-γ, PDGF and VEGF was 
observed, along with a decrease in eotaxin compared to the control group (p < 0.05). A poor correlation between 
IL-6 levels in tear and blood was found. IL-1RA and GM-CSF were significantly lower in severe patients and those 
who needed treatment targeting the immune system (p < 0.05). Tear cytokine levels corroborate the inflam-
matory nature of SARS-CoV-2.   
1. Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is 
responsible for the coronavirus disease 2019 (COVID-19). COVID-19 is 
considered a pandemia by the World Health Organization and is having 
a great impact globally. It causes a wide range of clinical manifestations 
that vary from mild symptoms like fever, cough and asthenia to severe 
complications, that can eventually lead to death(Guan et al., 2020). 
Cytokines play a significant role as essential mediators of the in-
flammatory response during a viral infection. An adequate, fast and 
well-coordinated innate immune response is crucial as the first line of 
defense against viruses(Ye et al., 2020). SARS-CoV-2 not only triggers an 
innate immune system response that releases cytokines and chemokines, 
but also activates the adaptive immune system by which T and B cells 
also release inflammatory cytokines(Crisci et al., 2020). 
COVID-19 patients present a characteristic cytokine profile in serum, 
which has been investigated by many groups. Huang et al., (2020) re-
ported higher blood levels of interleukin (IL)-1β, IL-1RA (IL-1 receptor 
antagonist), IL-7, IL-8, IL-9, IL-10, fibroblast growth factor basic (FGF 
basic), granulocyte colony-stimulating factor (G-CSF), 
granulocyte-monocyte colony-stimulating factor (GM-CSF),interferon 
(IFN)-γ, interferon gamma-induced protein (IP10), monocyte 
chemo-attractant protein-1 (MCP-1), macrophage inflammatory protein 
(MIP)-1A, MIP-1B, platelet-derived growth factor (PDGF), tumor ne-
crosis factor (TNF)-α, and vascular endothelial growth factor (VEGF) in 
patients infected with SARS-CoV-2 compared healthy adults. In Chi 
et al.’s series(Chi et al., 2020), in addition to those found by Huang et al., 
higher serum levels of IL-2, IL-2Rα, IL-6, IL-13, IL-15, IL-17, IL-18 and 
IFN-α2 were detected in symptomatic patients in comparison to controls. 
Eotaxin levels were lower in symptomatic cases than healthy controls. 
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This intense cytokine secretion particularly occurs in severe and 
critical patients, being key in disease progression and the ultimate death 
of patients infected with SARS-CoV-2(Henderson, 2020; Ruscitti et al., 
2020; Ye et al., 2020). Liu et al., (2020) reported that IL-1RA, IL-1α, IL-2, 
IL-4, IL-7, IL-10, IL-12, IL- 17, IP-10, PDGF, TNF-α, IFN-γ, GM-CSF, 
G-CSF and hepatocyte growth factor (HGF) were associated with lung 
injury and disease severity. Huang et al.’s (Huang et al., 2020) com-
parison between critical and non-critical patients showed that IL-2, IL-7, 
IL-10, G-CSF, IP10, MCP-1, MIP-1A, and TNF-α concentrations were 
higher in the plasma ICU (intensive care unit) patients than non-ICU 
patients. Yang et al., (2020) also identified IP10, MCP-3, and IL-1RA 
as biomarkers for severity and worse outcomes of the disease. 
Hence, effectively suppressing the cytokine storm may serve as an 
important mechanism to prevent the aggravation of patients with 
COVID-19. In this regard, targeting treatment to reduce cytokine levels, 
such as glucocorticoids, intravenous immunoglobulins, tocilizumab 
(anti-IL-6) and anakirna (anti-IL-1 receptor), may improve prognosis 
(Soy, 2020). 
Tears are accessible and non-invasive sources from which bio-
markers can be obtained. Recently, tear analysis has proven to be a 
useful biomarker in many ocular surface and systemic diseases(ten 
Berge et al., 2019; Burgos-Blasco et al., 2020). Diabetic patients present 
a significant increase in the number of peaks when electrophoretic 
patterns from tear proteins when analyzed. This changes in protein 
patterns strongly correlated with the duration of the diabetic disease 
(Grus et al., 2002). Tear protein levels can also be upregulated or 
downregulated in breast cancer patients, as described by Böhm et al. 
They hypothezised that different biological processes may be altered in 
discrete fluids such as tears that are located far away from the original 
site(Böhm et al., 2012). However, tear cytokines in systemic diseases 
have not been fully assessed, nor has been correlation of blood and tear 
cytokines. 
SARS-CoV-2 has been recently detected in tears of COVID-19 pa-
tients, suggesting that the ocular surface and the tears might represent a 
potential route for SARS-CoV- 2 infection(Güemes-Villahoz et al., 2020). 
The exact route of entry is unknown and various theories including 
direct entry, through the nasolacrimal drainage system of the lacrimal 
gland have been proposed. To enter and infect cells, SARS-CoV-2 em-
ploys the angiotensin-converting enzyme 2 receptor (ACE2), which has 
been identified in the cornea, the conjunctiva, the retina and the 
choroid. Viral RNA detection in retinal biopsies supports the theory of 
direct entry of the virus in the eye, either through the ocular surface or 
through the hematogenous route(Casagrande et al., 2020; Güe-
mes-Villahoz et al., 2020). 
The main purpose of this study is to analyze cytokine levels in tears of 
hospitalized COVID-19 patients compared to healthy controls. Other 
objectives of this study were to assess the correlation and concordance 
between the values of IL-6 in tears and in serum of COVID-19 patients 
and to evaluate any association with clinical variables. To the best of our 
knowledge, this is the first study in the literature that analyzes the 
cytokine profile of tears of COVID-19 hospitalized patients and could 
provide valuable insight on immune system involvement. 
2. Methods 
2.1. Patients 
This is a cross-sectional study and has been conducted at the Hospital 
Clinico San Carlos in Madrid, Spain, a tertiary hospital that attends 
patients within the Madrid metropolitan area. Patients that had been 
admitted to the hospital due to laboratory-confirmed COVID-19 diag-
nosis were recruited. Healthy patients from a previous study performed 
in 2018 were used as controls. 
This study has been approved by the Clinical Research Ethics Com-
mittee and has been conducted in accordance with the Helsinki Decla-
ration. Informed consent was obtained from all patients. 
The general admission criteria according to the hospital’s protocol 
included: 1) <50 years of age without comorbidities with bilateral 
pneumonia, or unilateral pneumonia with respiratory failure (saturation 
<96% and respiratory rate> 20); or 2) > 50 years of age or patients with 
comorbidity: with pneumonia, respiratory failure (saturation <96% and 
respiratory rate> 20), or laboratory/clinical severity (arterial blood gas, 
hemogram, D-dimer, C reactive protein (CRP), procalcitonin, lactate 
dehydrogenase (LDH), transaminases). 
Inclusion criteria for the patients were: over 18 years of age; patient 
with positive reverse transcriptase–polymerase chain reaction (RT-PCR) 
test from nasopharyngeal swab for SARS-CoV-2, hospitalization because 
of COVID-19, and ability to give verbal consent. Patients admitted to the 
intensive care unit, as well as those unable or unwilling to give verbal 
consent were excluded from the study. 
For the control group, the inclusion criteria considered were as fol-
lows: over 40 years of age; absence of ophthalmological pathology, 
absence of systemic inflammatory or infectious diseases and no medi-
cations with known influence on immunological factors. 
The exclusion criteria for both groups were ocular surgery or an 
ocular laser procedure in the previous six months; concomitant 
ophthalmological pathology; and topical treatment. Patients who had 
been hospitalized for less than 10 days were included, that is, at the start 
of hospitalization, so as to be able to correlate with treatment and 
prognosis. 
To select patients, all the patients with hospitalization in the previ-
ous 10 days in the COVID unit were selected and checked for inclusion 
and exclusion criteria. After determining which patients could be 
included, they were informed about the study and if they consented, a 
sample was taken. The same technique was repeated every week 
recruiting consecutively the patients until enough patients had been 
included. 
2.2. Data collection 
Clinical charts, laboratory findings, and chest x-rays for all the pa-
tients included in the study were reviewed. Demographic, clinical, lab-
oratory, and radiological characteristics, along with treatment and 
outcomes were obtained from the electronic medical records. Two re-
searchers independently reviewed the data to double-check the 
collected data. 
Patients were classified according to the severity. Moderate cases 
had fever, respiratory tract symptoms, and radiological abnormalities, 
and the severe cases had at least 1 of the following: (1) respiration rate 
≥ 30 times/min, (2) oxygen saturation at rest ≤ 93%, (3) arterial Pao2/ 
Fio2 ≤ 300 mmHg, and (4) respiratory failure, shock, or other organ 
failure requiring intensive care unit treatment. No mild or critical cases 
were included in this study. 
To correlate with laboratory data, blood test results from the day the 
tear sample were used. IL-6 analysis was also performed on the same day 
as the tear sample. Regarding anti-inflammatory treatment, glucocorti-
coids, intravenous immunoglobulins and/or anti-cytokine therapies 
such as tocilizumab and anakinra were noted. 
2.3. Tear sample and cytokine determination 
The tear samples (3–5 μl) were collected with a 10 μl capillary tube. 
The tube was carefully placed in the inferior conjunctival fornix so as not 
to cause reflex stimulation. Samples from both eyes were obtained with 
the same capillary tube. In the laboratory, the samples were stored at 
− 80 ◦C. All procedure followed infection control and prevention mea-
sures according to the hospital’s protocol. 
The cytokine levels in the tear samples were analyzed using the Bio- 
Plex Pro Human Cytokine 27-Plex Immunoassay kit (Bio-Rad Labora-
tories, Hercules, CA, USA). The concentration of 27 pro-inflammatory 
cytokines were determined: IL-1b, IL-1RA, IL- 2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin, FGFbasic, G-CSF, GM- 
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CSF, IFN-γ, IP-10, MCP-1, MIP)-1A, MIP-1B, PDGF, regulated on acti-
vation, normal T cell expressed and secreted (RANTES), TNF-α and 
VEGF. 
Cytokine concentrations were quantified by interpolating the fluo-
rescence intensities emitted measured with a Luminex MAGPIX reader 
(Luminex Corporation, Austin, TX, USA) against their standard curves. 
Bio-Plex ManagerTM software (Bio-Rad Laboratories, Hercules, CA, 
USA) was used to calculate the cytokine levels. 
2.4. Statistics 
The data were processed and analyzed statistically using IBM SPSS 
Statistics for Mac, version 21.0 (IBM Corp., Armonk, NY, USA). 
Continuous data is presented as mean and standard deviation, while 
categorical data is presented as frequencies and percentages. For cate-
gorical variables, frequency distributions were calculated and compared 
using the chi-square test. 
A Shapiro-Wilk test was performed to understand the distribution of 
the value across the cohort. To analyze the differences in the concen-
trations of each cytokine between the different subgroups a Mann 
Whitney U test was performed. The correlation between IL-6 in blood 
and tear was determined by Spearman correlation. A p-value < 0.05 was 
considered to be statistically significant. 
3. Results 
The overall study population included 103 subjects: 62 COVID-19 
patients (124 eyes) with laboratory-confirmed diagnosis of SARS-CoV- 
2 infection admitted at the hospital and 41 historic controls (82 eyes). 
Of the 584 patients in the COVID-unit, the first consecutive 80 pa-
tients that met the inclusion and exclusion criteria and consented to 
participation in the study were consecutively included. 18 patients 
presented too little tear and there was not enough sample for analysis; 9 
patients did not give verbal consent; 5 patients with previous history of 
ocular surgery or concomitant treatment were excluded: 1 patient had 
received intravitreal dexamethasone implant due to diabetic macular 
edema 5 weeks prior, 1 patient had received antiVEGF treatment due to 
age related macular degeneration 1 week prior; 1 patient underwent 
phacoemulsification surgery 2 months prior and 2 patients were using 
intraocular pressure IOP-lowering therapy. 
The main clinical characteristics found on the COVID-19 patients 
included are shown in Table 1. Among the 41 control subjects included, 
16 patients (39%) were male and the median age was 66.9 years (SD 
16.0 years). No statistically significant difference in the sex and age was 
found between both groups (p > 0.05). 
Mean days from onset of symptoms to hospitalization were 8.6 days 
(SD 6.2 days), while mean days from hospitalization to tear sampling 
was 3.7 days (SD 2.0 days). 
IL-1b, IL-2, IL-5, IL-7, IL-10, IL-12, IL-13, FGFb, MCP-1, MIP-1b and 
TNF-α were detected in fewer than 40% of samples and therefore were 
not included in further analysis. Shapiro-Wilk test revealed that the 
remaining variables were not normally distributed. 
Table 2 depicts the cytokine levels found in COVID-19 patients 
compared to the control group. A significant increase in IL-9, Il-15, G- 
CSF, GM-CSF, IFN-γ, PDGF and VEGF, as well as a decrease in eotaxin in 
tears of COVID-19 patients was found (Fig. 1). 
When comparing IL-6 blood and tear levels, the correlation (r = -.94) 
was not statistically significant (p = 0.489). Fig. 2 depicts the association 
between cytokine tear levels and severity of the disease and need for 
specific treatment targeting hypercytokinemia. IL-1RA and GM-CSF 
were significantly lower in severe patients and those who needed 
treatment targeting the immune system (p < 0.05). 
The correlation of cytokine tear levels with laboratory findings: 
neutrophils/lymphocytes ration, CPR, ferritin, D-dimer and LDH 
showed no statistically significant differences when corrected for mul-
tiple comparisons. Neither did comparison for cytokine tear levels 
between sex. 
4. Discussion 
Cytokines are a key factor in determining the clinical course of SARS- 
CoV-2 infection. A dysregulated or an exaggerated immune response by 
SARS-CoV-2 infected cells plays an important role in the infection’s 
pathogenesis. We analyzed the tear levels of 27 cytokines in a cohort of 
62 patients including moderate and severe cases with laboratory- 
confirmed COVID-19 in Madrid, Spain. Our results show an increase 
in IL-9, IL-15, G-CSF, GM-CSF, IFN-γ, PDGF and VEGF in the tears of 
COVID-19 patients compared to controls, all which have been reported 
to be increased in serum of COVID-19 patients(Chi et al., 2020; Huang 
Table 1 
COVID-19 patients’ characteristics.  
Patient characteristics All 
patients 






(n = 27) 
p 
Sociodemographic data  
Sex     
Male. N (%) 33 (53) 18 (51) 15 (56) 0.747 
Female. N (%) 29 (47) 17 (49) 12 (44) 0.747 
Age. Years (SD) 69.7 
(16.9) 
68.5 (18.5) 71.3 
(14.9) 
0.500 
Race     
Caucasic. N (%) 52 (84) 28 (80) 24 (89) 0.345 
Hispanic. N (%) 10 (16) 7 (20) 3 (11) 0.345 
Medical history  
AH. N (%) 35 (56) 18 (51) 17 (63) 0.364 
DM. N (%) 19 (31) 9 (26) 10 (37) 0.338 
DL. N (%) 32 (52) 17 (49) 15 (56) 0.585 
Chronic obstructive 
pulmonary disease. N 
(%) 
14 (23) 9 (26) 5 (19) 0.502 
Cardiovascular disease. 
N (%) 
22 (35) 11 (31) 11 (41) 0.447 
Chronic renal disease. N 
(%) 
7 (11) 2 (6) 5 (19) 0.114 
Chronic liver disease. N 
(%) 
3 (5) 2 (6) 1 (4) 0.715 
Malignancy. N (%) 6 (10) 2 (6) 4 (15) 0.229 
Clinical data  
Pneumonia. N (%) 42 (68) 21 (60) 21 (78) 0.138 
Hemoglobin. g/dL (SD) 12.3 (2.2) 12.4 (2.4) 12.1 (1.9) 0.516 
Leucocytes.103/μL (SD) 6.4 (2.6) 6.2 (2.1) 6.7 (3.1) 0.499 
Neutrophils. 103/μL 
(SD) 
4.5 (2.6) 3.9 (1.9) 5.3 (3.2) 0.064 
Linfocytes.103/μL (SD) 1.3 (0.8) 1.5 (0.7) 1.0 (0.8) 0.009** 
CPR. mg/dL (SD) 4.4 (6.2) 1.6 (1.9) 7.9 (8.0) <0.001** 




























IL-6. pg/mL (SD) 31.3 
(50.5) 






41 (66) 22 (63) 19 (70) 0.535 
Ritonavir/lopinavir. N 
(%) 
12 (19) 5 (14) 7 (26) 0.141 
Glucocorticoids. N (%) 19 (31) 4 (11) 15 (56) <0.001** 
Tocilizumab. N (%) 4 (6) 0 (0) 4 (15) 0.019 
Anti-inflammatory 
treatment. N (%) 
22 (35) 5 (14) 17 (63) <0.001** 
Clinical outcome  
Recovery. N (%) 57 (92) 35 (100) 22 (81) 0.007** 
Death. N (%) 5 (8) 0 (0) 5 (19) 0.007** 
SD: Standard deviation; AT: Arterial hypertension; DM: Diabetes mellitus; DL: 
dislypidemia; CRP: C-reactive protein; LDH: lactate dehydrogenase; IL-6: inter-
leukin 6. 
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et al., 2020). 
One of the most investigated cytokines in COVID-19 is IL-6, as it is 
one of the main mediators of the inflammatory and immune response. In 
fact, IL-6 levels at hospital admission are considered to have a good 
prognostic value for severe disease progression and/or in-hospital 
mortality(Grifoni et al., 2020). IL-6 can be more easily measured in 
blood than others cytokines and is therefore currently being used to 
evaluate hyperinflammation and the need for specific anti-inflammatory 
treatment in hospitalized COVID-19 patients. Because IL-6 is routinely 
measured in COVID-19 patients and correlation of tear and blood cy-
tokines has not been thoroughly investigated in systemic diseases, we 
decided to analyze whether a correlation between serum and tear IL-6 
levels exists. However, we found no such correlation, suggesting that 
although IL-6 can be produced in all tissues, it may be especially 
increased in blood. 
As for other cytokines found to be increased in tears, colony- 
stimulating factors such as GM-CSF and G-CSF stimulate the prolifera-
tion of granulocytes and macrophages, contributing to the maintenance 
of innate immune homeostasis. Recent evidence suggests that GM-CSF 
also enhances proinflammatory cytokine release and CD4+ T cell dif-
ferentiation(Shiomi and Usui, 2015). Interestingly, pathogenic Th1 cells 
with both IFN-γ and GM-CSF expression have been found in critical 
patients (Zhou et al., 2020). Our results support the role of GM-CSF in 
SARS-CoV-2 infection. 
In addition, IFN-γ, a Th1 cytokine mainly secreted by T and NK cells, 
has been described to be elevated in COVID-19 patients(Henderson, 
2020). There are conflicting results which describe a mild elevation of 
IFN-γ systemic levels in non-severe patients(Jamilloux et al., 2020). Our 
results reflect an increase in IFN-γ in tear of COVID-19 patients, but no 
association with severity was detected. 
VEGF tear levels were also increased in our study compared to 
controls. VEGF presents an important pro-angiogenic, mitogenic and 
anti-apoptotic effect on endothelial cells(Maharaj and D’Amore, 2007). 
In COVID-19, vascular alterations have been linked to acute lung injury 
and acute respiratory distress syndrome(Ciceri, 2020). Hence, increased 
serum and tear levels of VEGF may be associated to the procoagulant 
state characteristic of COVID-19 patients by increasing vascular 
permeability and altering the hemostatic features of endothelial cells 
(Connors and Levy, 2020). VEGF secretion is stimulated by IL-6 and IL-1, 
which are elevated in COVID-19, also linking VEGF to the immune 
response(Moore and June 2020). 
In the present study, COVID-19 patients had decreased levels of 
eotaxin-1. Interestingly, lower eotaxin levels have also been described in 
serum of COVID-19 patients(Chi et al., 2020). 
Additionally, we assessed the relationship between severity, treat-
ment and tear cytokine levels in COVID-19 patients. Our results report 
lower tear levels of IL1-RA and GM-CSF in severe patients compared to 
those with a moderate form of the disease. These cytokines also pre-
sented decreased levels in those patients who received treatment to 
target the cytokine storm. A possible association of GM-CSF with both 
CPR and LDH may exist, supporting its role in the inflammatory 
response to SARS-CoV-2, but no statistical significance was reached 
when correction for multiple comparisons was applied. The lack of 
correlation of more cytokines with severity, like those observed in blood, 
could be explained by the fact that patients with mild forms of the dis-
ease (not admitted to the hospital) and critically ill patients (no possi-
bility of giving consent) were not included. 
Cytokine ocular sources have not been fully elucidated, but it is 
believed that both inflammatory and structural (epithelial and fibro-
blast) cells act as local sources(Enríquez-de-Salamanca and Calonge, 
2008). In corneal surgery, IL-6 increases have been suggested to origi-
nate from epithelial cells and keratocytes(Malecaze et al., 1997). Simi-
larly, exposure of these cells to IL-1 or TNF-alpha was found to stimulate 
IL-8 synthesis(Cubitt et al., 1993). On the other hand, the retinal 
pigment epithelium can secrete cytokines, but under the control of cells, 
such as monocytes, present at a blood–retinal barrier breakdown, which 
could be possibly due to the vascular involvement of COVID-19(Wallace 
et al., 2004). Hence, tear cytokines may come directly from those pre-
sent in the blood or be a result of a response to systemic cytokines. The 
latter would explain why no direct correlation was found between IL-6 
tear and blood levels. However, there are not only many uncertainties 
about the origin of tear cytokines, but the investigations that exist are of 
ocular diseases and not systemic ones. Therefore, the different origins of 
these cytokines can only be hypothesized, but more studies are definitely 
needed in this regard. 
The following limitations should be considered when interpreting 
our findings. For the control group, a historical control group was used, 
since both PCR and serology do not have 100% sensitivity and present 
many false negatives. This was the only way to ensure that no asymp-
tomatic patients nor false negative cases were accidentally included. 
Table 2 
Cytokine levels in tear of COVID-19 patients compared to controls.  
Cytokines Control group (n = 41) COVID-19 (n = 62) p 
IL-1RA 10219.12 ± 20072.36 12497.95 ± 18423.12 0.562 
IL-4 3.16 ± 5.17 3.11 ± 5.13 0.960 
IL-6 10.71 ± 17.28 54.87 ± 245.28 0.163 
IL-8 423.47 ± 1222.22 331.45 ± 777.89 0.670 
IL-9 30.02 ± 73.43 79.91 ± 74.15 0.001** 
IL-15 742.02 ± 1702.32 2575.88 ± 2726.65 <0.001** 
IL-17A 24.43 ± 25.52 15.56 ± 18.94 0.061 
Eotaxin 11.55 ± 22.33 2.68 ± 8.39 0.019* 
G-CSF 248.51 ± 427.92 543.19 ± 781.12 0.015* 
GM-CSF 5.1 ± 13.83 18.42 ± 27.33 0.002** 
IFN-γ 77.21 ± 110.71 154.65 ± 197.1 0.012* 
IP-10 24494.77 ± 37384.68 13882.07 ± 42887.93 0.187 
MIP-1a 7.82 ± 7.47 8.73 ± 18.75 0.732 
PDGF 127.58 ± 237.44 242.75 ± 310.92 0.036* 
RANTES 75.4 ± 52.21 71.39 ± 41.89 0.681 
VEGF 1571.6 ± 3146.13 4141.32 ± 4387.04 0.001** 
Data are expressed as mean (pg/mL) ± standard deviation (SD). * (p < 0.05); ** 
(p < 0.01). 
Fig. 1. Tear cytokine levels in controls and COVID-19 patients. Data are expressed as mean (pg/mL) + standard deviation (SD). * (p < 0.05); ** (p < 0.01).  
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They did not differ in age and sex from the studied group. Most COVID- 
19 cohorts present a high male prevalence of up to 80%, while our 
sample presents a 55% of male patients. Male patients present usually a 
more severe form of the disease and were therefore difficult to include in 
this study, where collaboration and verbal consent was needed. 
To the best of our knowledge, no previous studies have evaluated the 
tear cytokine profile among hospitalized COVID-19 patients and 
compared it to healthy controls. There are few studies of tear cytokines 
in systemic diseases without ocular involvement and fewer correlating 
cytokines in tear and blood. 
The importance of this study not only lies in the relevance of the 
ocular inflammatory reaction, but also the possible direct involvement 
of the virus. SARS-CoV-2 detection in tears and ocular fluids rises 
concern for the safety of ophthalmological procedures. Because of the 
proximity necessary for an ophthalmological examination, the exposure 
to tears and the risk of aerosol generation, ophthalmologists are at high 
risk for SARS-CoV-2 infection(Güemes-Villahoz et al., 2020). Several 
ophthalmological societies have issued guidelines with recommended 
protocols, all agreeing that it is safest to assume that any patient is 
potentially infected, especially in high risk areas. Aerosol generation has 
been evaluated during phacoemulsification and should also be consid-
ered(Darcy et al., 2020). 
Hypercytokinemia with an uncontrolled proinflammatory response 
in SARS-CoV-2 plays an important role in the pathogenesis. SARS-CoV-2 
infection is a potent inducer of proinflammatory cytokines in tear, some 
of them correlating with severity. We believe that the cytokine tear 
pattern in COVID-19 could serve as biomarkers to evaluate the disease 
severity. Further investigation are needed to get a full picture of the 
spectrum of tear cytokine levels in SARS-CoV-2 infection. 
Data availability 
No data available. 
Funding 
No funding received. 
Declaration of competing interest 
The authors declare that they have no conflicts of interests. 
References 
Soy, Mehmet, et al., 2020. Cytokine storm in COVID-19: pathogenesis and overview of 
anti-inflammatory agents used in treatment. Clin. Rheumatol. 39 (7), 2085–2094. 
ten Berge, Josianne C., et al., 2019. Intraocular cytokine profile and autoimmune 
reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and 
cataract. Acta Ophthalmol. 97 (2), 185–192. 
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